Azadyne is a biotech spin-out company from Trinity College Dublin founded by Professors Stephen Connon, Vincent Kelly, Mike Southern and CEO, Dr. Jason Rutt, ex head of UK patents, Pfizer.
Get in touch today to learn more about the Azadyne story.
Our Innovative Technology
Confronting Autoimmune Disease
Azadyne's approach focuses on an unexplored pathway within the body and offers a novel approach to the treatment of autoimmune disease - a therapeutic area suffering from considerable unmet medical need. Our approach is based on the strategic design of derivatives of a natural micronutrient.
We have teamed-up with NCL Technology Ventures who led the recent funding round of €1.75M. The latest investment will help take Azadyne's lead compounds towards first-in-human trials.
Azadyne's aim is to exploit our innovative technology to disrupt the therapeutic options for autoimmune disease.